The grey market premium (GMP) for the issue stood at 36% ahead of the opening, implying an unofficial market price of around Rs 283 against the upper end of the issue band, a premium of roughly Rs 75 per share. A GMP of this magnitude points to strong pre-listing demand and suggests investors are pricing in a healthy listing-day gain, a sharp contrast to the muted grey market activity seen in several other SME issues opening this week.
Avience Biomedicals IPO is seeing strong pre-listing demand with a Grey Market Premium (GMP) of 36%. This implies an unofficial market price of around Rs 283, a premium of Rs 75 per share over the upper end of its issue band. This high GMP suggests investors expect healthy…
Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.